These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 9046927

  • 1. Benefits of lispro insulin: control of postprandial glucose levels is within reach.
    Bohannon NJ.
    Postgrad Med; 1997 Feb; 101(2):73-6, 79-80. PubMed ID: 9046927
    [Abstract] [Full Text] [Related]

  • 2. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.
    Diabetes Metab Res Rev; 2004 Feb; 20(1):55-60. PubMed ID: 14737746
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Insulin analogues: new agents for improving glycemic control.
    White JR, Campbell RK, Hirsch I.
    Postgrad Med; 1997 Feb; 101(2):58-60, 63-5, 70. PubMed ID: 9046926
    [Abstract] [Full Text] [Related]

  • 5. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR, Waters DL, Holcombe JH, Schade DS.
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [Abstract] [Full Text] [Related]

  • 6. Insulin lispro, a new insulin analog.
    Kucera ML, Graham JP.
    Pharmacotherapy; 1998 Mar; 18(3):526-38. PubMed ID: 9620104
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, Calderini MC, Coscelli C, Fedele D, Galluzzo A, Giordano M, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G.
    Nutr Metab Cardiovasc Dis; 2001 Jun; 11(3):168-75. PubMed ID: 11590992
    [Abstract] [Full Text] [Related]

  • 9. Insulin lispro: a fast-acting insulin analog.
    Noble SL, Johnston E, Walton B.
    Am Fam Physician; 1998 Jan 15; 57(2):279-86, 289-92. PubMed ID: 9456992
    [Abstract] [Full Text] [Related]

  • 10. Insulin lispro improves postprandial glucose control in patients with diabetes mellitus.
    Skrha J, Smahelová A, Andĕl M, Vrtovec M, Subić J, Kreze A, Vozar J, Korecová M, de Verga V, Wyatt J, Metcalfe S, Ristić S.
    Sb Lek; 2002 Jan 15; 103(1):15-21. PubMed ID: 12448933
    [Abstract] [Full Text] [Related]

  • 11. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Jan 15; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 12. Insulin lispro (Humalog) in the treatment of diabetes mellitus: overview of belgian clinical data from global studies.
    Bex M, Buysschaert M, De Leeuw I, De Schepper J, Fery F, Hermans MP, Keymeulen B, Lauvaux JP, Letiexhe M, Mathieu C, Nobels FR, Rottiers R, Scheen A, Schmitt H, Van Crombrugge P, Van Gaal L.
    Acta Clin Belg; 1999 Oct 15; 54(5):241-5. PubMed ID: 10555381
    [No Abstract] [Full Text] [Related]

  • 13. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M.
    Diabet Med; 1996 Jul 15; 13(7):625-9. PubMed ID: 8840095
    [Abstract] [Full Text] [Related]

  • 14. Insulin lispro.
    Holleman F, Hoekstra JB.
    N Engl J Med; 1997 Jul 17; 337(3):176-83. PubMed ID: 9219705
    [No Abstract] [Full Text] [Related]

  • 15. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH.
    Clin Ther; 2006 Oct 17; 28(10):1649-57. PubMed ID: 17157120
    [Abstract] [Full Text] [Related]

  • 16. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group.
    Clin Invest Med; 2001 Dec 17; 24(6):292-8. PubMed ID: 11767232
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis.
    Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, E Kitabchi A.
    Am J Med; 2004 Sep 01; 117(5):291-6. PubMed ID: 15336577
    [Abstract] [Full Text] [Related]

  • 18. Insulin analog lispro decreases insulin resistance and improves glycemic control in an obese patient with insulin-requiring type 2 diabetes.
    Darmon P, Curtillet C, Boullu S, Laugier A, Dutour A, Oliver C.
    Diabetes Care; 1998 Sep 01; 21(9):1575. PubMed ID: 9727917
    [No Abstract] [Full Text] [Related]

  • 19. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Sep 01; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 20. Cessation of insulin infusion at night-time during CSII-therapy: comparison of regular human insulin and insulin lispro.
    Reichel A, Rietzsch H, Köhler HJ, Pfützner A, Gudat U, Schulze J.
    Exp Clin Endocrinol Diabetes; 1998 Sep 01; 106(3):168-72. PubMed ID: 9710355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.